ArticleBiogerontology2025
Multi-omics profiling reveals mitochondrial dysfunction and epigenetic dysregulation in postoperative cognitive dysfunction: identification of novel biomarkers in an aged mouse model.
Article in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Postoperative cognitive dysfunction (POCD) is a prevalent neurocognitive disorder in elderly patients following surgery and anesthesia. However, the underlying mechanisms remain poorly understood, and treatment options are limited. This study applied a multi-omics strategy, combining cognitive-behavioral assessments with proteomic and metabolomic profiling, to uncover the molecular basis of POCD in an aged mouse model. Behavioral assessments, including the Morris Water Maze (MWM), Open Field Test (OFT), and Novel Object Recognition (NOR), revealed significant cognitive deficits in POCD mice. Proteomic analysis identified 103 differentially expressed proteins (DEPs), with 34 upregulated and 69 downregulated, alongside significant correlations among 16 proteins. Enrichment analysis indicated disturbances in mitochondrial energy metabolism and epigenetic regulation, linked to neurodegenerative pathways. Metabolomic profiling detected 99 metabolites, with 66 upregulated and 33 downregulated, confirming their differential expression between groups. Correlation analysis between DEPs and metabolites led to the identification of nine key proteins (PSB9, COA7, PFD2, CUTA, LEG1, LEG9, BET1L, CHIL3, KV5AG) as potential biomarkers and therapeutic targets for POCD. These findings emphasize the complex relationship between cognitive dysfunction, molecular alterations, and metabolic disruptions in POCD, suggesting a multifactorial pathogenesis that warrants further investigation to develop targeted interventions.
Indexed as
Identifiers
41361137What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.